Morgan Stanley Starts C4 Therapeutics (CCCC) at Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $3.06 -3.77%
Rating Summary:
11 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
11 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Underweight rating and a price target of $6.00.
For an analyst ratings summary and ratings history on C4 Therapeutics click here. For more ratings news on C4 Therapeutics click here.
Shares of C4 Therapeutics closed at $7.73 yesterday.
You May Also Be Interested In
- Citi Starts Yamazaki Baking Co Ltd (2212:JP) at Buy
- Needham Assumes Benchmark (BHE) at Buy
- Cantor Fitzgerald Starts Quantum Corp. (QMCO) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
